Articaine

Summary

Articaine (CHEMBL1093) is an approved small molecule (ATC N01BB58); indicated across 4 conditions including pulpitis and periodontitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N01BB58 (+1 more)
• Indications: 4 conditions
• Clinical trials: 40
• Chemistry: 284.38 Da · C13H20N2O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1093
Name	Articaine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	32170
ATC	N01BB58, N01BB08
Molecular formula	C13H20N2O3S
Molecular weight	284.38
InChIKey	QTGIAADRBBLJGA-UHFFFAOYSA-N

SMILES: CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC

IUPAC name: methyl 4-methyl-3-[2-(propylamino)propanoylamino]thiophene-2-carboxylate

Also known as: Articaina, Articaine, Carticaine, Septocaine, articaine, ARTICAINE, Articaine HCl

Parent form; salt/anhydrous children: CHEMBL1200819

Patent coverage: 1,706 distinct patent families (6,583 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Sodium channel alpha subunits; brain (Types I, II, III), 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR1A	5.72	AC50	1904	nM	CHEMBL_ACT_25165284

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pulpitis	3	MONDO:0006937	EFO:1001139
periodontitis	2	MONDO:0005076	EFO:0000649
kidney failure	0	MONDO:0001106	EFO:1002048

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 40.

Phase distribution

Phase	Trials
PHASE4	13
Not specified	13
PHASE2	5
PHASE3	3
PHASE1/PHASE2	3
EARLY_PHASE1	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07231614	PHASE4	NOT_YET_RECRUITING	Anesthetic Effectiveness of Lidocaine Versus Articaine in Dentistry
NCT01350050	PHASE4	COMPLETED	Topical Pharyngeal Anesthesia With Articaine for Gastroscopy
NCT01496846	PHASE4	COMPLETED	Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars
NCT01536717	PHASE4	SUSPENDED	Comparison of the Local Anaesthetics Articaine and Bupivacaine in Treatment of Acute Sternum Pain After Heart Surgery
NCT01862614	PHASE4	COMPLETED	Testing the Anesthetic Effectiveness of Buffered Articaine Injected Next to a Lower First Molar.
NCT01951820	PHASE4	COMPLETED	Comparison of Two Topical Anesthetics: Benzocaine Versus Pliaglis
NCT03318952	PHASE4	WITHDRAWN	Articaine vs Lidocaine for Pediatric Dental Procedures
NCT04166890	PHASE4	COMPLETED	Comparison of the Efficacy and Safety of Two Homologous Active Principles for Local Dental Anesthesia
NCT04186299	PHASE4	WITHDRAWN	The Effect of Buccal Infiltration Administration of Clonidine on the Success Rate of Inferior Alveolar Nerve Block
NCT04236115	PHASE4	COMPLETED	Comparison of Articaine and Prilocaine for Extraction of Maxillary Teeth
NCT05252117	PHASE4	UNKNOWN	Uterovaginal Plexus Block With Articaine for Intrauterine Device Placement Patients Who Are Indicated for the Use of Copper IUD as a Contraceptive Method Will be Invited to Participate in This Research.
NCT05443009	PHASE4	COMPLETED	Self-Reported Pain in Children Submitted to Single Infiltration of Articaine During Primary Molar Extraction
NCT06161714	PHASE4	UNKNOWN	The Effectiveness of Buccal Infiltration Only Using Articaine for Extraction of Mandibular Molar
NCT05839548	PHASE3	ACTIVE_NOT_RECRUITING	Articaine Efficacy and Safety for 3 Years Old Children
NCT00247741	PHASE3	COMPLETED	Spinal Anesthesia With Articaine and Lidocaine for Outpatient Surgery.
NCT00332735	PHASE3	COMPLETED	Spinal Anesthesia With Articaine and Bupivacaine for Outpatient Lower Limb Surgery
NCT06538233	PHASE2	RECRUITING	Pain After Buffered Vs Non Buffered Articaine
NCT03962634	PHASE2	TERMINATED	Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Pediatric
NCT04061265	PHASE1/PHASE2	COMPLETED	Articaine Efficacy and Safety for Children Below Age of 4-years
NCT04104789	PHASE2	WITHDRAWN	Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - General
NCT04105985	PHASE2	WITHDRAWN	Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics
NCT05200884	PHASE1/PHASE2	COMPLETED	Local Anesthesia With Lidocaine or Articaine for Molars Affected by MIH
NCT05585112	PHASE1/PHASE2	COMPLETED	Articaine 4% Versus Lidocaine 2% for Local Anesthesia of MIH-affected Maxillary Molars
NCT05840913	PHASE2	COMPLETED	Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis
NCT04189198	PHASE1	COMPLETED	A Comparison of 4% Articaine Versus 0.5%Bupivacaine for Ambulatory Surgery Under Supraclavicular Block
NCT03612323	EARLY_PHASE1	UNKNOWN	Comparison Between Intraligamentary Piroxicam and Articaine
NCT04171349	EARLY_PHASE1	COMPLETED	Articaine vs Dexmedetomidine Supplemented Articaine
NCT06423859	Not specified	RECRUITING	Articaine Plus Dexmedetomidine in Supraclavicular Block
NCT07066306	Not specified	ACTIVE_NOT_RECRUITING	Effects of Local Ketamine in Orthognathic Procedures
NCT07604337	Not specified	NOT_YET_RECRUITING	Pre-emptive Local Anesthesia and Emergence Behavior After Pediatric Dental General Anesthesia
NCT02422823	Not specified	COMPLETED	Anesthetic Efficacy of 1,8mL and 3,6mL of Articaine in Inferior Alveolar Nerve Block in Irreversible Pulpitis
NCT02726620	Not specified	COMPLETED	Decision Support for Intraoperative Low Blood Pressure
NCT03942991	Not specified	UNKNOWN	Anesthetic Efficacy Of 4% ArtpharmaDent Versus 2% Mepecaine-L in Extraction of Lower First Primary Molars
NCT04822415	Not specified	COMPLETED	Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis
NCT05101785	Not specified	UNKNOWN	Articaine 4% Efficacy and Safety in Extraction and Pulpotomy of Primary Molars of Children Below the Age of Four Years
NCT05728151	Not specified	COMPLETED	Comparing General Anesthesia With Single Injection Peribulbar Block With 3 Different Drugs
NCT05944341	Not specified	UNKNOWN	Articaine Efficiency in Pulpectomy of Children With Irreversible Pulpitis Under the Age of Four
NCT06025825	Not specified	UNKNOWN	Comparative Effect of Palatal Injection in Pediatric Patient
NCT07018115	Not specified	COMPLETED	Anxiety and Hemodynamic Changes in Third Molar Extraction After Patient Education
NCT07145879	Not specified	COMPLETED	Comparison of Postoperative Effects of Articaine and Lidocaine in Mucogingival Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).